Kai Wang1, Jessica Zarzour2, Soroush Rais-Bahrami3, Jennifer Gordetsky4. 1. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. 2. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL. 3. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL; Department of Urology, University of Alabama at Birmingham, Birmingham, AL. 4. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL; Department of Urology, University of Alabama at Birmingham, Birmingham, AL. Electronic address: jgordetsky@uabmc.edu.
Abstract
OBJECTIVE: To investigate clear cell papillary (CCP) renal cell carcinoma (RCC), an uncommon tumor of low malignant potential characterized by low-grade, clear cells, showing papillary and tubular architecture. This relatively newly described entity is still being characterized. We present our series of CCP RCC with new clinical and imaging findings. MATERIALS AND METHODS: We reviewed the clinical, pathologic, and imaging findings of 28 CCP RCCs in 21 patients identified from our institution between 2010 and 2016. RESULTS: Sixteen of 21 (76%) patients were African American with an equal male-to-female ratio. Mean follow-up was 26.1 ± 16.9 months. Mean age at diagnosis was 58.3 ± 10.7 years, and mean preoperative creatinine was 2.7 ± 2.9 mg/dL. End-stage renal disease or chronic kidney disease was present in 10 of 21 (47.6%) patients. Mean tumor size was 2.2 ± 1.5 cm. All cases were stage pT1, and 25 of 28 (89%) tumors were grade 2. No necrosis or sarcomatoid features were identified. Two patients had synchronous clear cell RCC and 1 patient had synchronous papillary RCC. No recurrence or metastases were identified. On imaging, the majority of the lesions were solid, with relatively low-level enhancement, similar to papillary RCC, with regions of heterogeneous hyper-enhancement, similar to clear cell RCC. The rate of growth on serial imaging was comparable with that observed for other low-staged RCCs. CONCLUSION: In our series, CCP RCC was seen more commonly in African American patients and associated with end-stage renal disease or chronic kidney disease. Imaging characteristics are similar in both clear cell RCC and papillary RCC. A nephron-sparing approach is recommended when surgically feasible.
OBJECTIVE: To investigate clear cell papillary (CCP) renal cell carcinoma (RCC), an uncommon tumor of low malignant potential characterized by low-grade, clear cells, showing papillary and tubular architecture. This relatively newly described entity is still being characterized. We present our series of CCP RCC with new clinical and imaging findings. MATERIALS AND METHODS: We reviewed the clinical, pathologic, and imaging findings of 28 CCP RCCs in 21 patients identified from our institution between 2010 and 2016. RESULTS: Sixteen of 21 (76%) patients were African American with an equal male-to-female ratio. Mean follow-up was 26.1 ± 16.9 months. Mean age at diagnosis was 58.3 ± 10.7 years, and mean preoperative creatinine was 2.7 ± 2.9 mg/dL. End-stage renal disease or chronic kidney disease was present in 10 of 21 (47.6%) patients. Mean tumor size was 2.2 ± 1.5 cm. All cases were stage pT1, and 25 of 28 (89%) tumors were grade 2. No necrosis or sarcomatoid features were identified. Two patients had synchronous clear cell RCC and 1 patient had synchronous papillary RCC. No recurrence or metastases were identified. On imaging, the majority of the lesions were solid, with relatively low-level enhancement, similar to papillary RCC, with regions of heterogeneous hyper-enhancement, similar to clear cell RCC. The rate of growth on serial imaging was comparable with that observed for other low-staged RCCs. CONCLUSION: In our series, CCP RCC was seen more commonly in African American patients and associated with end-stage renal disease or chronic kidney disease. Imaging characteristics are similar in both clear cell RCC and papillary RCC. A nephron-sparing approach is recommended when surgically feasible.
Authors: Alberto Diaz de Leon; Ali Pirasteh; Daniel N Costa; Payal Kapur; Hans Hammers; James Brugarolas; Ivan Pedrosa Journal: Radiographics Date: 2019-06-14 Impact factor: 5.333
Authors: Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou Journal: Mod Pathol Date: 2021-03-04 Impact factor: 8.209
Authors: Aleksandra Wilk; Barbara Wiszniewska; Dagmara Szypulska-Koziarska; Paulina Kaczmarek; Maciej Romanowski; Jacek Różański; Marcin Słojewski; Kazimierz Ciechanowski; Małgorzata Marchelek-Myśliwiec; Elżbieta Kalisińska Journal: Biol Trace Elem Res Date: 2017-03-09 Impact factor: 3.738
Authors: Dominik A Barth; Ondrej Slaby; Christiane Klec; Jaroslav Juracek; Rares Drula; George A Calin; Martin Pichler Journal: Cancers (Basel) Date: 2019-10-17 Impact factor: 6.639
Authors: Ee Jean Lim; Khi Yung Fong; Jingqiu Li; Hong Hong Huang; Kenneth Chen; Kae Jack Tay; Christopher Wai Sam Cheng; Henry Sun Sien Ho; Nye Thane Ngo; John Shyi Peng Yuen Journal: Investig Clin Urol Date: 2022-03
Authors: Stanley Weng; Renzo G DiNatale; Andrew Silagy; Roy Mano; Kyrollis Attalla; Mahyar Kashani; Kate Weiss; Nicole E Benfante; Andrew G Winer; Jonathan A Coleman; Victor E Reuter; Paul Russo; Ed Reznik; Satish K Tickoo; A Ari Hakimi Journal: Eur Urol Date: 2020-10-10 Impact factor: 20.096